Skip to main content

Table 5 Comparison of Response in HBsAg-positive patients treated with or without rituximab

From: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma

  Use of rituximab (N = 27) (33.3%) No rituximab (N = 54) (66.7%) p-value
Complete response 19 (70.4) 24(44.4) 0.16
Partial response 6 (22.2) 25(46.3)  
Stable disease 1(3.7) 3(5.6)  
Progressive disease 1(3.7) 2(3.7)